Latest / Stock Movers / Lilly to Buy Centessa Pharmaceuticals; Biogen to Buy Apellis; Unilever Foods Exit
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg data.
- 0:16Speaker 1: Let's take a look at some stocks on the move today.
- 0:18Speaker 1: I'm Nathan Hager, joined by Bloomberg's Isabelle Lee, trying to
- 0:21Speaker 1: keep up with all the red headlines that just cross
- 0:24Speaker 1: the Bloomberg terminal with deal news in the pharma space.
- 0:28Speaker 1: A couple of headlines getting sparked here. Good morning, Isabelle.
- 0:33Speaker 3: Good morning Nason. I don't need coffee because my heart
- 0:36Speaker 3: is something because the headlines just keep coming in. Let's
- 0:39Speaker 3: first start with Lily. Shares are hired by nearly one percent,
- 0:42Speaker 3: so Lily is set to buy some intents the pharmaceuticals
- 0:46Speaker 3: for thirty eight dollars a share in cash plus one
- 0:49Speaker 3: transferable contingent value that entitles the holder to get up
- 0:53Speaker 3: an aggregate of nine dollars, which is subject to the
- 0:55Speaker 3: achievement of certain milestones in this day list three. Total
- 1:00Speaker 3: potential aggregate per share will be around forty seven dollars
- 1:03Speaker 3: per share. Of course, it's big news to see the wires,
- 1:06Speaker 3: and it's up by nearly one percent. This is really
- 1:09Speaker 3: big news for us this morning. Should I go to
- 1:11Speaker 3: the second one.
- 1:12Speaker 2: Because yeah, please do me.
- 1:13Speaker 3: Yeah, the second one is Biogen. This one's the stock
- 1:17Speaker 3: is slipped actually by zero point eight percent in pre
- 1:19Speaker 3: market trade and now it's up again by point twenty percent.
- 1:23Speaker 3: So you see the stock there, see sawing between gains
- 1:25Speaker 3: and losses. So Biogen has agreed to acquire a Palace Pharmaceuticals, Inc.
- 1:30Speaker 3: For five point six billion dollars to expand its treatments
- 1:34Speaker 3: and immuneology and rare diseases. So Biogen will pay forty
- 1:38Speaker 3: one dollars a share for a Palace gaining two approved
- 1:41Speaker 3: drugs which is five fove and empavelli I try my
- 1:45Speaker 3: best there and new and blood disorders and a rare
- 1:49Speaker 3: kidney diseases. So we know that this acquisition is part
- 1:52Speaker 3: of Biogen's efforts to really find new sources of growth
- 1:55Speaker 3: under their new CEO, and really as the company tries
- 1:58Speaker 3: to get back it's multiple sclerosis franchise which has in declining.
- 2:03Speaker 1: So a lot of pharma deal news as we get
- 2:05Speaker 1: ready to close out the first quarter here while we
- 2:07Speaker 1: wait for some potential deal news. It could be historic
- 2:12Speaker 1: for Unilever and McCormick.
- 2:14Speaker 3: Yes, so I want to pivot to this because this
- 2:16Speaker 3: is when I think of McCormick, I think a breakfast.
- 2:19Speaker 3: I guess it's all despices.
- 2:20Speaker 2: So I think of old day.
- 2:22Speaker 3: So yeah, yes, timely for us. So indeed, we have
- 2:26Speaker 3: McCormick shares up by nearly four and a half percent.
- 2:30Speaker 3: We do have you and Laver in talks to sell
- 2:33Speaker 3: most of its food business to McCormick, and those talks
- 2:35Speaker 3: are advanced and a final deal could be announced later
- 2:38Speaker 3: today Tuesday. This is historic and for both companies this
- 2:42Speaker 3: deal is the biggest in their histories, and it will
- 2:44Speaker 3: also help Unilever be recast as a global leader and
- 2:48Speaker 3: not only beauty and personal but also in home care. Also,
- 2:52Speaker 3: it will catapult McCormick into a global spice, seasoning and
- 2:57Speaker 3: condiments giant. So definitely good time for us to think
- 3:00Speaker 3: about this because it's nearing breakfast. So. Unilever does not
- 3:03Speaker 3: provide further details on equity components, but said the deal
- 3:07Speaker 3: will be when it's completed, it will have around sixty
- 3:10Speaker 3: five percent of the combined company, so definitely some big
- 3:14Speaker 3: news and Unilever will still have majority control.
- 3:17Speaker 1: We've also got some big news going back to the
- 3:20Speaker 1: pharma space, but not so good news, it seems for.
- 3:23Speaker 3: Pepgen not looking good. The stock plunge around forty six
- 3:29Speaker 3: percent in pre market trade. The biotech firm release disappointing
- 3:32Speaker 3: clinical data. So the set data involves I'm being tested
- 3:36Speaker 3: here myotonic this trophy type one treatment, and analysts have
- 3:42Speaker 3: mixed mixed sentiments regarding that data. We have Oppenheimer saying
- 3:47Speaker 3: that the cello might be overdone. That's the only positive,
- 3:50Speaker 3: but a lot are loop forms. This defaul, for example,
- 3:53Speaker 3: said it's it's a mixed bat and it's being received
- 3:56Speaker 3: negatively by investor.
- 3:59Speaker 2: This stock moves report from Bloomberg Radio. Check back with
- 4:03Speaker 2: us throughout the day for the latest roundup of companies
- 4:06Speaker 2: making news on Wall Street and for the latest market
- 4:09Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 4:13Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 4:17Speaker 2: the Bloomberg Business app.